Smith & Nephew ANNuAl report 2013 102 FiNANCiAl StAtemeNtS Notes to the Group accounts continued The following tables present revenue, profit, asset and liability 1 Basis of preparation continued information regarding the Groups operating segments.
Investments The exchange rates used for the translation of currencies into in associates and loans to associates are segmentally allocated to US Dollars that have the most significant impact on the Group Advanced Surgical Devices.
results were: 2.1 Revenue by business segment and geography 2013 2012 2011 Average rates ACCOUNTING POLICY Sterling 1.56 1.58 1.60 Revenue comprises sales of products and services to third Euro 1.33 1.28 1.39 parties at amounts invoiced net of trade discounts and rebates, Swiss Franc 1.08 1.07 1.13 excluding taxes on revenue.
Revenue from the sale of products is recognised upon transfer to the customer of the significant Year-end rates risks and rewards of ownership.
This is generally when goods Sterling 1.66 1.63 1.55 are delivered to customers.
Sales of inventory located at Euro 1.38 1.32 1.29 customer premises and available for customers immediate use are recognised when notification is received that the product Swiss Franc 1.12 1.09 1.06 has been implanted or used.
Appropriate provisions for returns, trade discounts and rebates are deducted from revenue.
Rebates 2 Business segment information comprise retrospective volume discounts granted to certain customers on attainment of certain levels of purchases from the For management purposes, the Group is organised into business Group.
These are accrued over the course of the arrangement segments according to the nature of its products and has two based on estimates of the level of business expected and reportable business segments Advanced Surgical Devices and adjusted at the end of the arrangement to reflect actual volumes.
The types of products and services offered by each business segment are: Smith & Nephews Advanced Surgical Devices ASD business offers the following products and technologies: 2013 2012 2011 $ million $ million $ million Orthopaedic Reconstruction which includes Hip Implants, Knee Implants and ancillary products such as bone cement and Revenue by business segment mixing systems used in cemented reconstruction joint surgery Advanced Surgical Devices 3,015 3,108 3,251 Trauma & Extremities consisting of internal and external devices Advanced Wound Management 1,336 1,029 1,019 used in the stabilisation of severe fractures and deformity correction procedures 4,351 4,137 4,270 Sports Medicine Joint Repair, which offers surgeons a broad There are no material sales between business segments.
array of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints 2013 2012 2011 Arthroscopy Enabling Technologies which offer healthcare $ million $ million $ million providers a variety of technologies such as fluid management equipment for surgical access, high definition cameras, digital Revenue by geographic market image capture, scopes, light sources and monitors to assist with United States 1,862 1,651 1,756 visualisation inside the joints, radio frequency wands, United Kingdom 293 297 291 electromechanical and mechanical blades, and hand instruments for removing damaged tissue Other Established Markets 1,633 1,706 1,769 Other ASD which includes gynaecological instrumentation and Emerging & International Markets 563 483 454 the remaining Clinical Therapies geographies which are in the 4,351 4,137 4,270 process of being transferred to Bioventus.
Smith & Nephews Advanced Wound Management AWM Revenue has been allocated by basis of destination.
No revenue business offers a range of products: from a single customer is in excess of 10% of the Groups revenue.
Advanced Wound Care includes products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns and post-operative wounds Advanced Wound Devices consists of traditional and single-use Negative Pressure Wound Therapy and hydrosurgery systems Advanced Wound Bioactives includes biologics and other bioactive technologies that provide unique approaches to debridement and dermal repair regeneration.
Management monitors the operating results of its business segments separately for the purposes of making decisions about resource allocation and performance assessment.
Group financing including interest receivable and payable and income taxes are managed on a Group basis and are not allocated to business segments.
Group StrAteGiC report CorporAte GoverNANCe FiNANCiAl StAtemeNtS AND other iNFormAtioN Smith & Nephew ANNuAl report 2013 FiNANCiAl StAtemeNtS 103 2.2 Trading and operating profit by business segment Trading profit is a trend measure which presents the long-term profitability of the Group excluding the impact of specific transactions that management considers affects the Groups short-term profitability.
The Group presents this measure to assist investors in their understanding of trends.
The Group has identified the following items, where material, as those to be excluded from operating profit when arriving at trading profit: acquisition and disposal related items including amortisation of acquisition intangibles and impairments: significant restructuring events: gains and losses arising from legal disputes: and uninsured losses.
Operating profit reconciles to trading profit as follows: 2012 2011 2013 Restated Restated Notes $ million $ million $ million Operating profit 810 846 862 Acquisition-related costs 3 31 11 Restructuring and rationalisation expenses 3 58 65 40 Amortisation of acquisition intangibles and impairments 9 88 43 36 Legal provision 3 23 Trading profit 987 965 961 Trading profit by business segment Advanced Surgical Devices 712 728 714 Advanced Wound Management 275 237 247 987 965 961 Operating profit by business segment reconciled to attributable profit for the year Advanced Surgical Devices 620 632 630 Advanced Wound Management 190 214 232 Operating profit 810 846 862 Net interest receivable payable 4 2 8 Other finance costs 11 11 13 Share of results of associates 1 4 Profit on disposal on net assets held for sale 251 Taxation 246 371 266 Attributable profit for the year 556 721 575 2.3 Assets and liabilities by business segment and geography 2013 2012 2011 $ million $ million $ million Balance sheet Assets: Advanced Surgical Devices 3,684 3,518 3,396 Advanced Wound Management 1,848 1,776 819 Operating assets by business segment 5,532 5,294 4,215 Assets held for sale relating to Advanced Surgical Devices 125 business segment Unallocated corporate assets 287 348 407 Total assets 5,819 5,642 4,747 Liabilities: Advanced Surgical Devices 609 530 526 Advanced Wound Management 308 256 169 Operating liabilities by business segment 917 786 695 Liabilities directly associated with assets held for sale 19 relating to Advanced Surgical Devices business segment Unallocated corporate liabilities 855 972 846 Total liabilities 1,772 1,758 1,560 Smith & Nephew ANNuAl report 2013 104 FiNANCiAl StAtemeNtS Notes to the Group accounts continued 2 Business segment information continued Unallocated corporate assets and liabilities comprise the following: 2013 2012 2011 $ million $ million $ million Deferred tax assets 145 164 223 Retirement benefit asset 5 6 Cash at bank 137 178 184 Unallocated corporate assets 287 348 407 Long-term borrowings 347 430 16 Retirement benefit obligations 230 266 287 Deferred tax liabilities 50 61 66 Bank overdrafts and loans due within one year 44 38 306 Current tax payable 184 177 171 Unallocated corporate liabilities 855 972 846 2013 2012 2011 $ million $ million $ million Capital expenditure including acquisitions Advanced Surgical Devices 327 188 334 Advanced Wound Management 124 839 31 451 1,027 365 Capital expenditure segmentally allocated above comprises: 2013 2012 2011 $ million $ million $ million Additions to property, plant and equipment 242 197 229 Additions to intangible assets 98 68 92 Capital expenditure excluding business combinations 340 265 321 Acquisitions Goodwill 53 73 44 Acquisitions Intangible assets 53 662 Acquisitions Property, plant and equipment 5 27 Capital expenditure 451 1,027 365 2013 2012 2011 $ million $ million $ million Depreciation, amortisation and impairment Advanced Surgical Devices 268 274 259 Advanced Wound Management 93 38 38 361 312 297 Group StrAteGiC report CorporAte GoverNANCe FiNANCiAl StAtemeNtS AND other iNFormAtioN Smith & Nephew ANNuAl report 2013 FiNANCiAl StAtemeNtS 105 Amounts comprise depreciation of property, plant and equipment, amortisation of other intangible assets, impairment of investments and amortisation of acquisition intangibles and impairments as follows: 2013 2012 2011 $ million $ million $ million Amortisation of acquisition intangibles 88 43 36 Depreciation of property, plant and equipment 209 212 217 Impairment of goodwill in Austrian associate 4 Amortisation of other intangible assets 64 51 42 Impairment of investments 2 2 361 312 297 No impairments were recognised within operating profit in 2013 2012 $6m, 2011 $2m, both recognised within the administrative expenses line.
In 2012 and 2011, the impairments were segmentally allocated to Advanced Surgical Devices.
Geographic 2013 2012 $ million $ million Assets by geographic location United States 2,086 2,122 United Kingdom 255 257 Other Established Markets 902 895 Emerging & International Markets 170 54 Non-current operating assets by geographic location 3,413 3,328 United States 1,121 999 United Kingdom 288 279 Other Established Markets 486 528 Emerging & International Markets 224 160 Current operating assets by geographic location 2,119 1,966 Unallocated corporate assets see page 104 287 348 Total assets 5,819 5,642 2.4 Other business segment information 2013 2012 2011 $ million $ million $ million Other significant expenses recognised within operating profit Advanced Surgical Devices 51 57 32 Advanced Wound Management 38 19 8 89 76 40 The $89m incurred in 2013 relates to $58m restructuring and rationalisation expenses and $31m acquisition-related costs 2012 $65m relates to restructuring and rationalisation expenses and $11m acquisition-related costs, 2011 $40m relates to restructuring and rationalisation expenses.
2013 2012 2011 numbers numbers numbers Average number of employees Advanced Surgical Devices 7,066 7,194 7,611 Advanced Wound Management 3,970 3,283 3,132 11,036 10,477 10,743
